Publications by authors named "V Borghi"
Article Synopsis
- The study analyzed HIV-1 sequences from 2386 drug-naïve individuals in Italy from 2015 to 2021 to assess the prevalence of transmitted drug resistance (TDR) among them.
- TDR prevalence was found to be 8%, with a slight difference between B subtypes (9.5%) and non-B subtypes (6.1%), and it remained stable over the years assessed.
- The research indicated that certain subtypes were associated with lower TDR rates, emphasizing the need for ongoing monitoring of TDR in newly diagnosed HIV patients to improve treatment strategies.
Article Synopsis
- - The study assessed the effectiveness of monoclonal antibodies Casirivimab and Imdevimab (CAS/IMV) in hospitalized patients with severe COVID-19, focusing on the risk of mechanical ventilation (MV) and death after 28 days.
- - Conducted in Italy, the observational study included 480 patients for modeling and 157 for testing, finding that age, PaO/FiO ratio, lactate dehydrogenase (LDH), and platelet counts were significant predictors of MV or death.
- - A risk score was developed from these predictors with good accuracy, indicating a lower mortality risk than previously reported; however, CAS/IMV is no longer in use.
Background: First-line integrase strand transfer inhibitor-based regimens have become commonly used in clinical practice over the last decade. This study aimed to analyse and compare the efficacy and safety of bictegravir (BIC) and dolutegravir (DTG) when prescribed in association with emtricitabine/tenofovir alafenamide (FTC/TAF) as part of a first-line regimen for the treatment of human immunodeficiency-1 (HIV-1) infection.
Methods: Treatment-naïve people living with HIV (PLWHIV) starting a first-line regimen with either BIC/FTC/TAF (BIC group) or FTC/TAF+DTG (DTG group) were analysed.
Background: The aim of this randomized clinical trial (RCT) was to compare immunological changes in virally suppressed people living with HIV (PLWH) switching from a three-drug regimen (3DR) to a two-drug regimen (2DR).
Methods: An open-label, prospective RCT enrolling PLWH receiving a 3DR who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir/lamivudine (DTG/3TC) was performed. Blood was taken at baseline and months 6 and 12.
Real-life comparisons of dolutegravir/rilpivirine (DTG/RPV) and DTG/lamivudine (3TC) regimens in people living with human immunodeficiency virus (PLWHIV) who switched from a standard three-drug regimen based on nonnucleoside reverse transcriptase inhibitors (NNRTIs) are missing. This study aimed to compare DTG/3TC and DTG/RPV in virologically suppressed patients (HIV-RNA < 50 copies/mL) coming from any NNRTI-based regimen in terms of discontinuation due to virologic failure (VF) discontinuation rates due to all causes, and adverse events. As a secondary outcome, we evaluated the difference in creatinine, total cholesterol, CD4, and triglycerides from baseline to weeks 48 after the switch.
View Article and Find Full Text PDF